Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CCR2 | P41597 | 4/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20070279 | 0.89 | RET (0.45) | RETSMN1; SMN2CCR2EPHX1PRKD1 | |
| SCHEMBL20148003 | 0.88 | RET (0.44) | RETSMN1; SMN2CCR2EPHX1 | |
| SCHEMBL21652056 | 0.86 | RET (0.43) | RETSMN1; SMN2CCR2EPHX1 | |
| SCHEMBL20158747 | 0.86 | RET (0.43) | RETSMN1; SMN2CCR2EPHX1CTSD | |
| SCHEMBL20069782 | 0.68 | RET (0.42) | RETSMN1; SMN2CYP2C19MAPTTSHR | |
| SCHEMBL10232878 | 0.67 | PIK3CD (0.42) | EPHX1 | |
| SCHEMBL21652001 | 0.67 | RET (0.42) | RETSMN1; SMN2MAPTTSHR | |
| SCHEMBL20069765 | 0.64 | CYP2C19 (0.44) | RETSMN1; SMN2EPHX1CYP2C19 | |
| SCHEMBL5330574 | 0.63 | CYP2D6 (0.39) | EPHX1HPGDCYP2C19CTSDMAPT | |
| SCHEMBL20069487 | 0.63 | RET (0.48) | RETSMN1; SMN2HPGDMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | RET 1/4885SMN1; SMN2 646/4885CCR2 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.